Zealand takes on Takeda's IBD drug with tiny buy­out

Af­ter years de­vel­op­ing a pep­tide to treat short bow­el syn­drome (SBS), Zealand Phar­ma is join­ing the hunt for the white whale of the gas­troin­testi­nal track: in­flam­ma­to­ry bow­el dis­ease.

The Dan­ish biotech is buy­ing out Toron­to-based En­cy­cle Ther­a­peu­tics for up to $80 mil­lion to ac­quire their lead pep­tide, ET3764, along with a bank of ap­prox­i­mate­ly 5,000 unique pep­tide macro­cy­cles. The pre­clin­i­cal drug has the same mech­a­nism as En­tyvio (vedolizum­ab), Take­da’s block­buster ul­cer­a­tive col­i­tis and Crohn’s dis­ease treat­ment – both forms of IBD. The big pitch is that En­cy­cle’s drug is oral, as op­posed to the En­tyvio in­fu­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER